NCT06254261View on ClinicalTrials.gov

A Study of RAY1225 in Participants With Obesity

PHASE2RecruitingINTERVENTIONAL

Enrollment

270

Participants

Timeline

Start Date

February 21, 2024

Primary Completion Date

December 20, 2025

Study Completion Date

December 20, 2025

Conditions

Obesity

Interventions

DRUG

RAY1225

Administered SC

DRUG

Placebo

Placebo

Trial Locations (1)

Unknown

RECRUITING

Peking University People's Hospital, Beijingcun

All Listed Sponsors

lead

Guangdong Raynovent Biotech Co., Ltd

INDUSTRY